BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9517989)

  • 1. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.
    Brosgart CL; Louis TA; Hillman DW; Craig CP; Alston B; Fisher E; Abrams DI; Luskin-Hawk RL; Sampson JH; Ward DJ; Thompson MA; Torres RA
    AIDS; 1998 Feb; 12(3):269-77. PubMed ID: 9517989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
    Spector SA; McKinley GF; Lalezari JP; Samo T; Andruczk R; Follansbee S; Sparti PD; Havlir DV; Simpson G; Buhles W; Wong R; Stempien M
    N Engl J Med; 1996 Jun; 334(23):1491-7. PubMed ID: 8618603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ganciclovir shows benefit for prevention of CMV disease in liver transplant recipients.
    J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):43-4. PubMed ID: 11363747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
    Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
    Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
    Gane E; Saliba F; Valdecasas GJ; O'Grady J; Pescovitz MD; Lyman S; Robinson CA
    Lancet; 1997 Dec; 350(9093):1729-33. PubMed ID: 9413463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
    Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
    Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
    Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
    JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
    Martin DF; Kuppermann BD; Wolitz RA; Palestine AG; Li H; Robinson CA
    N Engl J Med; 1999 Apr; 340(14):1063-70. PubMed ID: 10194235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ganciclovir.
    Schouten JT
    STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
    Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
    Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.